Program planning and continual evaluation have been critical for the development of the Cancer Therapy & Research Center (CTRC) and its research infrastructure. CTRC uses both internal and external sources for review and evaluation, soliciting input from Cancer Center experts. The CTRC External Advisory Board is the primary external mechanism for review and advice on the CTRC and its progress in both clinical and basic research. CTRC has also utilized smaller ad hoc advisory groups for Cancer Center Administration, Shared Resources and Programs. Internal mechanisms for planning and evaluation center around the CTRC Executive Committee (EC), which includes the CTRC Associate Directors and Program Leaders, as well as the CTRC Internal Advisory Board (lAB) and the CTRC Shared Resources Oversight Committee. The lAB includes Senior Leaders from the University of Texas Health Science Center (UTHSCSA), who meet annually to provide feedback on CTRC's progress in clinical and research arenas at the UTHSCSA. The Shared Resources Oversight Committee aids the Center through annual evaluation of the CTRC Shared Resources as well as by making recommendations with respect to CTRC Shared Resources. ! A key part of the CTRC planning and evaluation process has been the development of a CTRC Strategic Plan. A number of groups including those mentioned above have had a role in the strategic planning process. The CTRC Strategic Plan was developed and organized in accordance with the Six Essential Characteristics of NCI-Designated Cancer Centers. A critical element of the CTRC Strategic Plan is the renewed focus of the CTRC on serving its catchment area and understanding cancer in our predominantly Hispanic population. Other areas of focus include expansion of team science in the CTRC, outreach to other institutions of higher education in the area, and targeted recruitment of faculty to build the clinical and research enterprise of the CTRC.
The continuously ongoing planning and evaluation processes of the CTRC have been a critical component of the rebuilding that has occurred over the past funding period. A sustained focus on the CTRC Strategic Plan will be key to its growth and success.
| Gong, Siqi; Tomusange, Khamis; Kulkarni, Viraj et al. (2018) Anti-HIV IgM protects against mucosal SHIV transmission. AIDS 32:F5-F13 |
| Soteros, Breeanne M; Cong, Qifei; Palmer, Christian R et al. (2018) Sociability and synapse subtype-specific defects in mice lacking SRPX2, a language-associated gene. PLoS One 13:e0199399 |
| Gelfond, Jonathan; Goros, Martin; Hernandez, Brian et al. (2018) A System for an Accountable Data Analysis Process in R. R J 10:6-21 |
| De La Chapa, Jorge J; Singha, Prajjal Kanti; Lee, Debbie R et al. (2018) Thymol inhibits oral squamous cell carcinoma growth via mitochondria-mediated apoptosis. J Oral Pathol Med 47:674-682 |
| Katti, Sachin; Her, Bin; Srivastava, Atul K et al. (2018) High affinity interactions of Pb2+ with synaptotagmin I. Metallomics 10:1211-1222 |
| Hariharan, Nisha; Ashcraft, Keith A; Svatek, Robert S et al. (2018) Adipose Tissue-Secreted Factors Alter Bladder Cancer Cell Migration. J Obes 2018:9247864 |
| Wang, Zhonghua; Bhattacharya, Akash; White, Tommy et al. (2018) Functionality of Redox-Active Cysteines Is Required for Restriction of Retroviral Replication by SAMHD1. Cell Rep 24:815-823 |
| Deng, Yilun; Qin, Yuejuan; Srikantan, Subramanya et al. (2018) The TMEM127 human tumor suppressor is a component of the mTORC1 lysosomal nutrient-sensing complex. Hum Mol Genet 27:1794-1808 |
| Wei, Zhen; Panneerdoss, Subbarayalu; Timilsina, Santosh et al. (2018) Topological Characterization of Human and Mouse m5C Epitranscriptome Revealed by Bisulfite Sequencing. Int J Genomics 2018:1351964 |
| Chiang, Huai-Chin; Zhang, Xiaowen; Zhao, Xiayan et al. (2018) Gene-Specific Genetic Complementation between Brca1 and Cobra1 During Mouse Mammary Gland Development. Sci Rep 8:2731 |
Showing the most recent 10 out of 989 publications
